blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4463181

EP4463181 - ANTI-COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1 (CTHRC1) ANTIBODIES AND METHODS OF USING THE SAME [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  18.10.2024
Database last updated on 28.03.2026
FormerThe international publication has been made
Status updated on  14.07.2023
Most recent event   Tooltip14.01.2026New entry: Renewal fee paid 
Applicant(s)For all designated states
Phenomic AI
661 University Avenue, Suite 1300
Mars Centre, West Tower
Toronto, Ontario M5G 0B7 / CA
For all designated states
Cooper, Sam
C/o Phenomic AI
661 University Avenue, Suite 1300
Mars Centre, West Tower
Toronto, Ontario M5G 0B7 / CA
For all designated states
Nixon, Allison
c/o Phenomic AI
661 University Avenue, Suite 1300
Mars Centre, West Tower
Toronto, Ontario M5G 0B7 / CA
For all designated states
London, Max
c/o Phenomic AI
661 University Avenue, Suite 1300
Mars Centre, West Tower
Toronto, Ontario M5G 0B7 / CA
For all designated states
Koch, Elizabeth
c/o Phenomic AI
661 University Avenue, Suite 1300
Mars Centre, West Tower
Toronto, Ontario, M5G 0B7 / CA
For all designated states
Harvey, Christopher
c/o Phenomic AI
661 University Avenue, Suite 1300
Mars Centre, West Tower
Toronto, Ontario M5G 0B7 / CA
For all designated states
Briskin, Michael
c/o Phenomic AI
661 University Avenue, Suite 1300
Mars Centre, West Tower
Toronto, Ontario M5G 0B7 / CA
[2024/47]
Inventor(s)01 / COOPER, Sam
Toronto Ontario, M5G 0B7 / CA
02 / NIXON, Allison
Toronto, Ontario, M5G 0B7 / CA
03 / LONDON, Max
Toronto, Ontario, M5G 0B7 / CA
04 / KOCH, Elizabeth
Toronto, Ontario, M5G 0B7 / CA
05 / HARVEY, Christopher
Toronto, Ontario, M5G 0B7 / CA
06 / BRISKIN, Michael
Toronto, Ontario, M5G 0B7 / CA
 [2024/47]
Representative(s)Secerna LLP
The Old Fire Station
18 Clifford Street
York YO1 9RD / GB
[2024/47]
Application number, filing date23737685.010.01.2023
[2024/47]
WO2023US10527
Priority number, dateUS202263298194P10.01.2022         Original published format: US 202263298194 P
[2024/47]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2023133360
Date:13.07.2023
Language:EN
[2023/28]
Type: A2 Application without search report 
No.:EP4463181
Date:20.11.2024
Language:EN
The application published by WIPO in one of the EPO official languages on 13.07.2023 takes the place of the publication of the European patent application.
[2024/47]
Search report(s)International search report - published on:US16.11.2023
ClassificationIPC:C07K16/18, C07K14/705, A61K39/00
[2026/04]
CPC:
C07K16/18 (EP,KR,US); A61K47/68031 (EP,KR,US); A61K47/6843 (EP,KR,US);
A61P35/00 (EP,KR,US); C07K14/525 (EP); C07K14/7051 (EP);
C07K14/70578 (EP,KR,US); C07K14/78 (EP); A61K2039/505 (EP,US);
C07K2317/24 (US); C07K2317/33 (EP,US); C07K2317/565 (US);
C07K2317/622 (EP,KR,US); C07K2317/732 (US); C07K2317/76 (EP,KR,US);
C07K2317/77 (EP,KR,US); C07K2317/92 (EP,US); C07K2319/00 (EP,US);
C07K2319/03 (EP); C07K2319/33 (EP); C07K2319/75 (EP) (-)
Former IPC [2024/47]A61K39/395, A61K38/39, A61K39/00, C07K14/78, C07K16/18, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   ME,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/47]
TitleGerman:1 (CTHRC1)-ANTIKÖRPER ENTHALTENDE ANTI-KOLLAGEN-TRIPLE HELIX REPEAT UND VERFAHREN ZU DEREN VERWENDUNG[2024/47]
English:ANTI-COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1 (CTHRC1) ANTIBODIES AND METHODS OF USING THE SAME[2024/47]
French:ANTICORPS ANTI-PROTÉINE 1 À RÉPÉTITION TRIPLE HÉLICE DE COLLAGÈNE (CTHRC1) ET MÉTHODES D'UTILISATION ASSOCIÉES[2024/47]
Entry into regional phase09.08.2024National basic fee paid 
09.08.2024Search fee paid 
09.08.2024Designation fee(s) paid 
09.08.2024Examination fee paid 
Examination procedure09.08.2024Examination requested  [2024/47]
04.03.2025Amendment by applicant (claims and/or description)
Fees paidRenewal fee
17.12.2024Renewal fee patent year 03
13.01.2026Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI] WO2020250204  (PRESTIGE BIOPHARMA PTE LTD et al.) [X] 1,9,12,17-19 * The whole document, in particular, the examples *[I] 1-2,4-5,8-10,12-19
 [XI]   CUI XIAO-XIAO ET AL: "Inhibition of CTHRC-1 by its specific monoclonal antibody attenuates cervical cancer cell metastasis", BIOMEDICINE & PHARMACOTHERAPY, vol. 110, 1 February 2019 (2019-02-01), pages 758 - 763, XP085573720, ISSN: 0753-3322, DOI: 10.1016/J.BIOPHA.2018.12.017 [X] 1 * The whole document, in particular, Fig.3, 4 * [I] 1-2,4-5,8-10,12-19

DOI:   http://dx.doi.org/10.1016/j.biopha.2018.12.017
 [XI]   ZHANG XUE-LI ET AL: "CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-[beta] receptors in colorectal cancer", ONCOGENE, NATURE PUBLISHING GROUP UK, LONDON, vol. 40, no. 23, 13 May 2021 (2021-05-13), pages 3959 - 3973, XP037479182, ISSN: 0950-9232, [retrieved on 20210513], DOI: 10.1038/S41388-021-01827-0 [X] 1 * The whole document, in particular, the results and discussion * [I] 1-2,4-5,8-10,12-19

DOI:   http://dx.doi.org/10.1038/s41388-021-01827-0
International search[XA] WO2020250204  (PRESTIGE BIOPHARMA PTE LTD et al.) [X] 1-2 * ; Paragraph [159], *[A] 3-9
 [A] US2009220521  (KERSCHBAUMER RANDOLF et al.) [A] 3 * ; Paragraph [0048] *
 [A] US2016223563  (YANCOPOULOS GEORGE D et al.) [A] 3 * ; Paragraph [0217] *
 [A] US2019135906  (DASILVA-JARDINE PAUL et al.) [A] 4,7,9 * ; Paragraph [0148] *
 [A] WO2019209974  (HENRY M JACKSON FOUND ADVANCEMENT MILITARY MEDICINE INC et al.) [A] 4, 7, 9 * ; Paragraph [00124] . *
 [A] WO2012021786  (THERACLONE SCIENCES INC et al.) [A] 4,7,9 * ; Paragraph [496] *
 [A] US2021380675  (SACHEN KACEY LAYN et al.) [A] 5 * ; Paragraph [0040] *
 [A] WO2021212049  (UNIV WASHINGTON et al.) [A] 5 * ; Paragraph [0270] *
 [A] US2021047407  (CHRISTIAN TWINKLE R et al.) [A] 6, 8-9 * ; Paragraph [0012] *
 [A] US2020109194  (CHU ISABEL MILAN et al.) [A] 6, 8-9 * ; Paragraph [0015] *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.